128 related articles for article (PubMed ID: 32517420)
1. CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML.
Satlsar ES; Mosleh M; Mehrpouri M
Turk J Haematol; 2020 Nov; 37(4):287-289. PubMed ID: 32517420
[No Abstract] [Full Text] [Related]
2. Report of a new six-panel flow cytometry marker for early differential diagnosis of APL from HLA-DR negative Non-APL leukemia.
Mosleh M; Mehrpouri M; Ghaffari S; Saei Z; Agaeipoor M; Jadali F; Satlsar ES; Gholampour R
Scand J Clin Lab Invest; 2020; 80(2):87-92. PubMed ID: 31829759
[TBL] [Abstract][Full Text] [Related]
3. Comment: In Response to "CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML".
Gajendra S
Turk J Haematol; 2020 Nov; 37(4):289-290. PubMed ID: 33236622
[No Abstract] [Full Text] [Related]
4. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells.
Touzet L; Dumezy F; Roumier C; Berthon C; Bories C; Quesnel B; Preudhomme C; Boyer T
Cancer Med; 2019 Mar; 8(3):1279-1288. PubMed ID: 30740913
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AML-M5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML).
Gorczyca W
Methods Cell Biol; 2004; 75():665-77. PubMed ID: 15603447
[No Abstract] [Full Text] [Related]
6. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
[TBL] [Abstract][Full Text] [Related]
7. Positive and negative predictive values of HLA-DR and CD34 in the diagnosis of acute promyelocytic leukemia and other types of acute myeloid leukemia with recurrent chromosomal translocations.
Promsuwicha O; Auewarakul CU
Asian Pac J Allergy Immunol; 2009 Dec; 27(4):209-16. PubMed ID: 20232575
[TBL] [Abstract][Full Text] [Related]
8. [Clinical analysis of HLA-DR-negative non-M3 AML].
Mori H; Sakai H; Sanada M; Shimamoto K; Sasaki S; Azuma R; Higuchi T; Harada H; Niikura H; Omine M; Fujita K; Takahashi N
Rinsho Ketsueki; 2007 Jul; 48(7):547-53. PubMed ID: 17695303
[TBL] [Abstract][Full Text] [Related]
9. Stepwise discriminant function analysis for rapid identification of acute promyelocytic leukemia from acute myeloid leukemia with multiparameter flow cytometry.
Chen Z; Li Y; Tong Y; Gao Q; Mao X; Zhang W; Xia Z; Fu C
Int J Hematol; 2016 Mar; 103(3):306-15. PubMed ID: 26759321
[TBL] [Abstract][Full Text] [Related]
10. HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia.
Oelschlaegel U; Mohr B; Schaich M; Schäkel U; Kroschinsky F; Illmer T; Ehninger G; Thiede C
Cytometry B Clin Cytom; 2009 Sep; 76(5):321-7. PubMed ID: 19291801
[TBL] [Abstract][Full Text] [Related]
11. [Immunophenotypic features in 143 cases of acute promyelocytic leukemia].
Sun HM; Qian SX; Wu YJ; Qiao C; Hong M; Fan L; Yang H; Zhang JF; Zhang SJ; Wu HX; Qiu HX; Lu H; Xu W; Sheng RL; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):176-9. PubMed ID: 19236773
[TBL] [Abstract][Full Text] [Related]
12. Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry.
Gupta M; Jafari K; Rajab A; Wei C; Mazur J; Tierens A; Hyjek E; Musani R; Porwit A
Cytometry B Clin Cytom; 2021 Jul; 100(4):409-420. PubMed ID: 33301193
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities.
Dong HY; Kung JX; Bhardwaj V; McGill J
Am J Clin Pathol; 2011 Jan; 135(1):76-84. PubMed ID: 21173127
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of acute myeloid leukemia without HLA-DR expression.
Moon H; Lee S; Huh J; Chung WS
Korean J Lab Med; 2007 Oct; 27(5):313-7. PubMed ID: 18094594
[TBL] [Abstract][Full Text] [Related]
15. The CD9
Ren F; Zhang N; Xu Z; Xu J; Zhang Y; Chen X; Tan Y; Chang J; Wang H
Int J Lab Hematol; 2019 Apr; 41(2):168-175. PubMed ID: 30315692
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia.
Zhou Y; Jorgensen JL; Wang SA; Ravandi F; Cortes J; Kantarjian HM; Medeiros LJ; Konoplev S
Am J Clin Pathol; 2012 Nov; 138(5):744-50. PubMed ID: 23086776
[TBL] [Abstract][Full Text] [Related]
17. PROFILE OF CD150 EXPRESSION IN BONE MARROW CELLS OF PATIENTS WITH ACUTE MYELOID LEUKEMIA.
Shlapatska L; Gordiienko I; Polishchuk A; Gluzman D
Exp Oncol; 2022 Nov; 44(3):198-207. PubMed ID: 36325710
[TBL] [Abstract][Full Text] [Related]
18. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.
Kaleem Z; Crawford E; Pathan MH; Jasper L; Covinsky MA; Johnson LR; White G
Arch Pathol Lab Med; 2003 Jan; 127(1):42-8. PubMed ID: 12521365
[TBL] [Abstract][Full Text] [Related]
20. Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.
van Luijn MM; Westers TM; Chamuleau ME; van Ham SM; Ossenkoppele GJ; van de Loosdrecht AA
Am J Pathol; 2011 Nov; 179(5):2157-61. PubMed ID: 21907692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
